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TWO NEW INVESTIGATORS
WIN BBMT EDITORIAL AWARDS
Two medical scientists are the re-
cipients of editorial awards for new
investigators, based on their articles
published this past year in Vol 8 of
Biology of Blood and Marrow Trans-
plantation.
● Recipient of the George Santos
Award for best clinical science pa-
per is Aaron E. Foster of West-
mead Institute for Cancer Re-
search, University of Sydney, New
South Wales, Australia.
● Recipient of the Ernest McCulloch
& James Till Award for best basic
science paper is Zhe Jiang, PhD,
of the University of Miami School
of Medicine, Miami, Fla.
The annual awards, each including
a $5,000 prize, are supported by ed-
ucational grants from StemCell Tech-
nologies Inc and StemSoft Software
Inc of Vancouver, British Columbia.
They were presented by Robert Korn-
gold, PhD, editor of BBMT, and Allen
Eaves, MD, PhD, president of the two
sponsoring companies.
The Foster winning article was “Cy-
tomegalovirus-Specific CD4 and
CD8 T-Cells Follow a Similar Recon-
stitution Pattern after Allogeneic Stem
Cell Transplantation” and appeared in
BBMT Vol 8, No 9.
Dr. Jiang’s winning article was “The
Contribution of Cytotoxic and Noncy-
totoxic Function by Donor T-Cells that
Support Engraftment after Alloge-
neic Bone Marrow Transplantation,”
which appeared in BBMT Vol 8, No
11.
Recipients of the two annual
awards must be not more than 5
years past a graduate or postdoctoral
program or a clinical research fellow-
ship, or currently active in a training
program as a clinical resident or fel-
low, postdoctoral fellow, medical
student, graduate student, or under-
graduate student. The judging com-
mittee is the BBMT Editorial Board
and the ASBMT Publications Commit-
tee.
ONLINE TUTORIAL HELPS EXPLAIN
NEW CPT CODES FOR BMT
A major overhaul of the CPT Codes
for hematopoietic stem cell collection
and transplantation took effect Janu-
ary 1. The new codes replaced the
previous limited number of codes
that over the years had become out-
dated and too vague to adequately
define stem cell transplantation pro-
cedures.
An online tutorial, posted on the
ASBMT Web site at www.asbmt.org,
provides transplanters and adminis-
trators details on the changes, includ-
ing codes that have been added, re-
vised, and deleted.
Also available on the Web site is a
PowerPoint presentation on the new
codes, based on presentations given
by James Gajewski, MD, at the med-
ical directors conference and the BMT
center administrators conference at
the Tandem BMT Meetings in Key-
stone, Colo. Getting the code revi-
sions to and through AMA commit-
tees was largely accomplished by Dr.
Gajewski, who chairs the ASBMT
Committee on CPT Codes, and Sam
Silver, MD, PhD, an ASBMT member
who chairs the Clinical Practice Com-
mittee for the American Society of He-
matology (ASH). The overall effort has
been a close collaboration of ASH and
ASBMT.
The new codes and their relative
values are based on complexity of the
procedure, the amount of physician
involvement, time required, intellec-
tual effort needed, health risk to the
patient, and potential liability.
Although the new codes are now
available for submitting claims to pri-
vate payers, the Centers for Medicare
and Medicaid Services (CMS) does not
yet recognize and accept all of the
new cell processing codes. Efforts to
attain CMS recognition of the cell pro-
cessing codes are continuing by the
ASBMT and ASH committees.
GERALDINE FERRARO OFFERS
PERSONAL MESSAGE IN ACCEPTING
ASBMT PUBLIC SERVICE AWARD
“This is not a death sentence. All of
you this evening make it possible for
me to say that,” said Geraldine Fer-
raro, speaking as a multiple myeloma
patient. “And I thank you for that. And
I thank you for this award.”
With these words, the former
member of Congress, U.N. ambassa-
dor, and 1984 vice presidential nom-
inee accepted the 2003 ASBMT Public
Service Award. Ms. Ferraro was hon-
ored for her accomplishments in
bringing national attention to blood
cancers, the need for medical re-
search funding, and the importance
of reducing the time it takes to de-
velop and launch new blood cancer
treatments.
“Living with any life-threatening ill-
ness makes each day even more of a
blessing,” she told the participants at
the 2003 Tandem BMT Meetings in a
videotaped message. “How long I will
feel as good as I do, only God knows
and She’s not telling. But look at the
progress that has already been made.
I am confident that, with time, a cure
will be found for multiple myeloma,
and I am also confident that until
then you doctors will work to find
ways to keep us patients alive,” she
said.
Ms. Ferraro created national news
when she took her illness public for
Congressional hearings that led to
last year’s enactment of legislation
that coordinated federal support and
authorized $275 million in new ex-
penditures for blood cancer research
and education programs.
“I had several goals in going public
with my illness,” she said. “I wanted to
raise awareness so that people would
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have their blood checked. I wanted
to get funding for blood cancer re-
search. And I wanted to get the FDA
to approve drugs faster. We have
made progress on all three.”
Focusing on drug innovations, she
said, “You all know how long it can
take to get FDA approval. You also
know that not all patients have the
luxury of time to wait. We can’t allow
people who need a drug to save their
life to then hear it is not available
because it is languishing in a pharma-
ceutical company’s lab. Or that it ex-
ists, but they can’t afford it. Or their
insurer won’t cover it,” she said.
“We need to keep reminding phar-
maceutical companies of their corpo-
rate responsibility to bring to market
not just the next knock-off ‘me too’
drug, but the developing drugs that
open doors of treatment and cure to
those with less common diseases.
Likewise, we need to keep pressure
on insurers to pay for evolving treat-
ments, and not simply retreat to a list
of the drugs they can get cheapest,”
she said.
In her 14-minute presentation, Ms.
Ferraro took time to share her per-
sonal experience with multiple my-
eloma—from its discovery in a routine
physical examination in 1998, to
treatment with steroids, to the option
of a bone marrow transplant which
was postponed in favor of treatment
with thalidomide. Her disease cur-
rently is inactive.
“How did I get multiple myeloma?
Was it the environment? Was it stress?
Was it some hidden genetic disposi-
tion?” she asked. “And why is it that
multiple myeloma manifests itself in
people who are older? Well, there are
currently no answers to those ques-
tions but, hopefully, someone here
tonight will be able to resolve them all
in the near future.”
She summarized her activism for
multiple myeloma since her diagnosis
as “the political person I am trying to
get things done. It’s really no big
deal. But what you all do on a daily
basis for me, and your patients, for
our families, for the American public
at large—that’s a very big deal and it
is what really deserves recognition
not only at an event such as this but
every day.”
The ASBMT Public Service Award is
determined each year by the society’s
officers and executive committee. The
award is supported by an educational
grant from SuperGen.
MEETINGS’ BEST ABSTRACTS CHOSEN
FROM RECORD 287 SUBMITTED
A record number of abstracts—287
from 30 countries—were accepted
for the recent Tandem BMT Meetings
in Keystone, Colo.
Six of the abstracts were singled
out for awards by the abstract review
committees.
Winning the ASBMT Best Abstract
Award for Outstanding Basic Science
Research were:
● Jeannie Hou, MD, National Can-
cer Institute, Bethesda, Md.
● Yukio Kondo, MD, M. D. Anderson
Cancer Center, Houston, Tex.
● Gerhard Hildebrandt, MD, Univer-
sity of Michigan Cancer Center,
Ann Arbor, Mich.
Winning the IBMTR/ABMTR Mor-
timer M. Bortin Award for Outstand-
ing Clinical Research were:
● Chang Q. Xun, MD, University of
Kentucky and V. A. Medical Cen-
ter, Lexington, Kentucky
● Susan Staba, MD, Duke University
Medical Center, Durham, N Caro-
lina
● Philip A. Rowlings, MBBS, MS,
Newcastle Mater Hospital, Wara-
tah Newcastle, Australia
The ASBMT best abstract awards
are supported by an unrestricted ed-
ucational grant from SuperGen. The
IBMTR/ABMTR best abstract awards
are supported by ILEX Oncology.
BMT FACILITIES IN KANSAS CITY,
BALTIMORE GAIN FACT APPROVAL
Two additional facilities have
gained accreditation by the Founda-
tion for Accreditation of Cellular Ther-
apy (FACT).
● Kansas City Blood and Marrow
Transplant Program, Kansas City,
Mo.—for allogeneic and autolo-
gous marrow and peripheral
blood progenitor cell transplanta-
tion, including collection and lab-
oratory processing.
● University of Maryland Green-
baum Cancer Center Blood and
Marrow Transplant Program, Balti-
more, Md.—for allogeneic and
autologous peripheral blood pro-
genitor cell transplantation, in-
cluding collection and laboratory
processing.
Currently there are 111 FACT-ac-
credited facilities, and another 102
are in various stages of the accredita-
tion process.
The accreditation renewal cycle
continues for facilities that previ-
ously achieved FACT accreditation.
The Providence Portland Medical
Center in Portland, Ore., is the latest
to be re-accredited for its autolo-
gous peripheral blood progenitor
cell transplantation program, in-
cluding collection and laboratory
processing.
FACT is a voluntary accrediting
agency sponsored by ASBMT and the
International Society for Cellular Ther-
apy (ISCT).
NEW FACT WEB SITE
The Foundation for Accreditation
of Cellular Therapy (FACT) has a new
Web site at www.factwebsite.org.
The site has a complete listing of all
FACT-accredited facilities, along with
the types of services each offers and
the name of the program director.
Soon to be included on the site are
the forms frequently used in the ac-
creditation process, in PDF format for
download: applications, fee sched-
ule, document checklists, guidelines
for applicants and the Inspection
Checklist.
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